Drug Trial Radar · NCT00849030
ATAC - Arimidex, Tamoxifen Alone or in Combination
Last checked: Nov 19, 2026Latest source record: Jun 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,358
Actual
Start
Jul 1996
Primary completion
Jun 2001
Study completion Apr 2010
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.
Conditions
- Breast Cancer
Interventions
Anastozole (Arimidex)Drug
1mg, orally, once daily
Tamoxifen (Nolvadex)Drug
20mg, orally, once daily
Anastozole (Arimidex) placeboDrug
1mg, orally, once daily
Tamoxifen (Nolvadex) placeboDrug
20mg, orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to recurrence of breast cancerTime frame: Earliest of local or distant recurrence, new primary breast cancer, or death
- Safety and side effectsTime frame: Earliest of local or distant recurrence, new primary breast cancer, or death
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.